- |||||||||| Nuvocid (oritavancin) / Melinta Therap, Zeven (dalbavancin) / RaQualia, AbbVie
Journal: On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections. (Pubmed Central) - Aug 13, 2020
In this real-world study in patients with Staphylococcal osteomyelitis and joint infection, DAL resulted in high rates of clinical and microbiological success. Prospective trials are needed to validate the use of these antibiotics for Gram-positive infections in practice, with the hope that they will reduce hospital LOS and the need for daily antibiotic infusions to provide alternative options for patients not qualifying for outpatient parenteral antimicrobial therapy.
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Trial completion date, Trial primary completion date: Hospital Avoidance Strategies for ABSSSI (clinicaltrials.gov) - Aug 8, 2020
P4, N=120, Recruiting,
Prospective trials are needed to validate the use of these antibiotics for Gram-positive infections in practice, with the hope that they will reduce hospital LOS and the need for daily antibiotic infusions to provide alternative options for patients not qualifying for outpatient parenteral antimicrobial therapy. Trial completion date: Jun 2020 --> Dec 2021 | Trial primary completion date: Mar 2020 --> Sep 2021
- |||||||||| vancomycin / Generic mfg., Zeven (dalbavancin) / RaQualia, AbbVie
Review, Journal: Infective endocarditis - can we treat it more effectively? (Pubmed Central) - Aug 1, 2020
This antibiotic is characterised by high clinical efficacy with good treatment tolerance and safety profile, without causing toxic effects in internal organs in comparison with vancomycin. In view of its safety, clinical efficacy and convenient dosing, dalbavancin may prove a useful therapeutic option in the treatment of IE.
- |||||||||| Review, Journal: The treatment of resistant staphylococcal infections. (Pubmed Central) - Jul 30, 2020
The near horizon holds promise also of augmentation of both cellular and humoral responses to staphylococcal infection. Pending newer clinical trials that show clear superiority of one anti-staphylococcal agent over another or over vancomycin, it will remain to expert clinical judgment in determining antibiotic choice and duration of anti-staphylococcal therapy.
- |||||||||| remdesivir / Generic mfg., Zeven (dalbavancin) / RaQualia, AbbVie
Review, Journal: COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks. (Pubmed Central) - Jul 29, 2020
As supported by recent clinical data, patients who have already taken lysosomotropic drugs for other pre-existing conditions likely benefit from this treatment in the COVID-19 pandemic. The early administration of a combination of antivirals such as remdesivir and lysosomotropic drugs, such as the antibiotics teicoplanin or dalbavancin, seems to be able to prevent SARS-CoV-2 infection and transition to COVID-19.
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Trial completion date, Trial primary completion date, Gram positive: Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections (clinicaltrials.gov) - Jul 20, 2020
P4, N=50, Recruiting,
The early administration of a combination of antivirals such as remdesivir and lysosomotropic drugs, such as the antibiotics teicoplanin or dalbavancin, seems to be able to prevent SARS-CoV-2 infection and transition to COVID-19. Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jul 2020 --> Jul 2021
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment change, Trial completion date, Trial termination: Xydalba Utilization Registry in Germany (clinicaltrials.gov) - Jul 17, 2020
P=N/A, N=16, Terminated,
Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jul 2020 --> Jul 2021 N=150 --> 16 | Trial completion date: Aug 2020 --> Apr 2020 | Recruiting --> Terminated; Terminated
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment closed: Xydalba Utilization Registry in France (clinicaltrials.gov) - Jul 14, 2020
P=N/A, N=151, Active, not recruiting,
N=150 --> 16 | Trial completion date: Aug 2020 --> Apr 2020 | Recruiting --> Terminated; Terminated Recruiting --> Active, not recruiting
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Preclinical, Journal: In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times. (Pubmed Central) - Jun 11, 2020
In this study, time-kill kinetics of dalbavancin against S. aureus and S. epidermidis biofilms were determined over prolonged exposure times (up to 7 days), using both a standardized biofilm susceptibility model and biofilms grown onto relevant orthopedic biomaterials (i.e. titanium and cobalt-chrome disks). Dalbavancin (at concentrations achievable in bone and articular tissue) showed a potent activity against established staphylococcal biofilms in both tested models, and was overall superior to the comparator vancomycin.
- |||||||||| vancomycin / Generic mfg., Zeven (dalbavancin) / RaQualia, AbbVie
Preclinical, Journal: A Silkworm Infection Model for In Vivo Study of Glycopeptide Antibiotics. (Pubmed Central) - Jun 11, 2020
Dalbavancin was more effective than first generation GPAs. Due to its great advantages (i.e., easy and safe handling, low rearing costs, low antibiotic amount needed for the tests, no restrictions imposed by ethical and regulatory issues), this silkworm infection model could be introduced in preclinical phases-prior to the use of mice-accelerating the discovery/development rate of novel GPAs.
- |||||||||| Journal: New antibiotics: an overview (Pubmed Central) - Jun 8, 2020
Two new glycopeptides (oritavancin and dalbavancin) and a new oxazolidinone (tedizolid) are now registered for the treatment of acute skin and soft-tissue infections...Examples of these are ceftolozane-tazobactam, ceftazidime-avibactam and meropenem-vaborbactam...There has been a great increase in investment in the development of new antimicrobials. Also, regulatory agencies have accelerated their assessment of these new - and urgently needed - drugs.
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Trial initiation date, Gram positive: Dalbavancin Outpatient Pilot (clinicaltrials.gov) - May 19, 2020
P4, N=24, Not yet recruiting,
Single-dose dalbavancin is an effective treatment option for outpatients with ABSSSI and is associated with a high degree of patient treatment satisfaction and convenience. Initiation date: May 2020 --> Aug 2020
- |||||||||| Sivextro (tedizolid) / Merck (MSD), Zeven (dalbavancin) / RaQualia, AbbVie
Journal: Current role of oxazolidinones and lipoglycopeptides in skin and soft tissue infections. (Pubmed Central) - May 15, 2020
We have reviewed the pharmacokinetic characteristics and the implications for use in skin and soft tissue infections of tedizolid and dalbavancin. Advantages associated with the use of these compounds include the possibility for early patient discharge, reduced hospital length of stay, and outpatient treatment, with potential impact on morbidity, mortality, and overall health-care costs.
- |||||||||| rifampicin / Generic mfg., Zeven (dalbavancin) / RaQualia, Allergan
Journal, Combination therapy: Effect of Dalbavancin on Staphylococcal Biofilms When Administered Alone or in Combination With Biofilm-Detaching Compounds. (Pubmed Central) - May 5, 2020
Thus, our data support the use of dalbavancin as a promising antimicrobial to treat biofilm-related infections. Our data also highlight that synergistic and antagonistic effects between antibiotics and biofilm-detaching compounds should be carefully tested in order to achieve an efficient treatment that could prevent both biofilm formation and disruption.
- |||||||||| Review, Journal: Glycopeptide Hypersensitivity and Adverse Reactions. (Pubmed Central) - Apr 25, 2020
Glycopeptides, such as vancomycin and teicoplanin, are primarily used in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections, such as cellulitis, endocarditis, meningitis, pneumonia, and septicemia, and are some of the most commonly prescribed parenteral antimicrobials...Also, we currently have the longer-acting lipoglycopeptides, such as dalbavancin, oritavancin, and telavancin to our armamentarium for the treatment of MRSA infections...Although hypersensitivity to glycopeptides is rare, both immune-mediated and delayed reactions have been reported in the literature. We describe the various types of glycopeptide hypersensitivity reactions associated with glycopeptides and lipoglycopeptides, including IgE-mediated reactions, RMS, and linear immunoglobulin A bullous dermatosis, as well as describe cross-reactivity with other glycopeptides.
- |||||||||| Zeven (dalbavancin) / RaQualia, Allergan
Journal: Dalbavancin Use in the Emergency Department Setting. (Pubmed Central) - Apr 24, 2020
Conclusion and Relevance: Our results suggest that patients may be safely administered DBV in an ED setting, with telehealth follow-up. Providing structured patient selection criteria is an effective method of assisting ED providers in selecting appropriate DBV candidates to limit potential recurrences and readmissions.
- |||||||||| Nuvocid (oritavancin) / Melinta Therap, Zeven (dalbavancin) / RaQualia, Allergan
Journal: VanZ Reduces the Binding of Lipoglycopeptide Antibiotics to Staphylococcus aureus and Streptococcus pneumoniae Cells. (Pubmed Central) - Apr 23, 2020
The reduction in the binding of fluorescently labeled teicoplanin to the cells suggests the mechanism of VanZ-mediated resistance. In addition, using a genomic vanZ gene knockout mutant of S. pneumoniae, we have shown that the ability of VanZ proteins to compromise the activity of lipoglycopeptide antibiotics by reducing their binding is a more general feature of VanZ-superfamily proteins.
- |||||||||| Zeven (dalbavancin) / RaQualia, Allergan
Clinical, Retrospective data, Journal: Safety and efficacy of prolonged use of dalbavancin in bone and joint infections. (Pubmed Central) - Mar 31, 2020
The results show that dalbavancin is a well-tolerated antibiotic, even when administering > 2 doses, and is associated with a high cure rate. This is preliminary data with a short follow-up, therefore, it is necessary to have more experience and in the future to establish the most appropriate dose and frequency.
- |||||||||| Zeven (dalbavancin) / RaQualia, Allergan
Journal: Activity of dalbavancin against gram-positive cocci isolated from skin and soft tissue infections in Poland. (Pubmed Central) - Mar 19, 2020
A total of 368 Gram-positive cocci from ABSSI were included in the study. S.aureus and S.pyogenes were susceptible to dalbavancin with MIC0.016mg/L and MIC0.032mg/L for MSSA and MIC0.032mg/L and MIC0.047mg/L for MRSA; MICs for S.pyogenes were ≤0.002-0.008mg/L; for E.faecalis and E.faecium, ranging 0.016-0.12mg/L and 0.012-≥32mg/L, respectively; MICs for VRE were 0.032-0.125mg/L.
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
Retrospective data, Journal, HEOR: Dalbavancin use in an academic medical center and associated cost-savings. (Pubmed Central) - Mar 5, 2020
A total of 617 hospital days were saved, estimated to be $1,495,336 in savings and a mean cost avoidance of $40,414 per patient. Dalbavancin provides a valuable antibiotic option that may minimize health care expenditures.
- |||||||||| dalbavancin / RaQualia
Journal: New Molecular Tools for Regulation and Improvement of A40926 Glycopeptide Antibiotic Production in Nonomuraea gerenzanensis ATCC 39727. (Pubmed Central) - Feb 13, 2020
Nonomuraea gerenzanensis ATCC 39727 is the most studied representative species since it produces the glycopeptide antibiotic (GPA) A40926 - the precursor of the clinically relevant antibiotic dalbavancin, approved by the FDA in 2014 for the treatment of acute skin infections caused by multi-drug resistant Gram-positive pathogens...Finally, the strongest constitutive promoter analyzed in this study, aac(3)IVp, was used to overexpress the cluster-situated regulatory genes controlling A40926 biosynthesis (dbv3 and dbv4 from N. gerenzanensis and nocRI from N. coxensis) in N. gerenzanensis, and the growth and productivity of the best performing strains were assessed at bioreactor scale using an industrial production medium. Overexpression of positive pathway-specific regulatory genes resulted in a significant increase in the level of A40926 production in N. gerenzanensis, providing a new knowledge-based approach to strain improvement for this valuable glycopeptide antibiotic.
- |||||||||| dalbavancin / RaQualia
Journal: Dalbavancin dosage. (Pubmed Central) - Feb 9, 2020
Overexpression of positive pathway-specific regulatory genes resulted in a significant increase in the level of A40926 production in N. gerenzanensis, providing a new knowledge-based approach to strain improvement for this valuable glycopeptide antibiotic. No abstract available
|
